Talk:Droxidopa

Flag errors on Droxidopa page. My name is Julia Simonsen, and I work for H Lundbeck A/S as Medical Information Specialist. My intent is to provide referenced and accurate information to the editors of Wikipedia for their use in Lundbeck related articles in order to help ensure that Wikipedia has the correct and latest information. Please see my user page JuliaSimonsen for information regarding my intentions for engagement on Wikipedia in alignment with their conflict of interest. I would like to flag the following errors on this page. Section: Indications To the NOH indication ‘dopamine beta hydroxylase deficiency’ should also be included and is supported by the Mathias 2008 reference

checked and corrected

Section: Clinical trials Suggest to remove this sentence since the trial has been completed and has been published: ‘To support additional indications beyond its approval in the US for NOH, phase II clinical trials for IDH are also underway’

Referring to the following sentence: Chelsea Therapeutics obtained orphan drug status (ODS) for droxidopa in the U.S. for NOH, and that of which associated with PD, PAF, and MSA, and is the pharmaceutical company developing it in that country. The last part of this sentence is incorrect (… and is the pharmaceutical company developing it in that country). Suggest to replace it with ‘In 2014, Chelsea Therapeutics was acquired by Lundbeck along with the rights to droxidopa which was launched in the US in September 2014’ http://investor.lundbeck.com/releasedetail.cfm?ReleaseID=846443 http://lundbeck.com/upload/us//files/pdf/2014_Releases/NORTHERA%20Availability%20press%20release%209.2.14.pdf

references checked and text corrected

Section: Side effects Suggest rewriting sentence: "The most common side effects reported in clinical trials include headache, dizziness, nausea, hypertension, and fatigue."

References http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203202lbl.pdf FDA reference checked and text corrected

Kaufmann H, Freeman R, Biaggioni I, et al. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology. 2014;83(4):328-35. Hauser RA, Isaacson S, Lisk JP, Hewitt LA, Rowse G. Droxidopa for the Short-Term Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Parkinson's Disease (nOH306B). Mov Disord. 2015;30

Comment throughout entire text: Inclusion of ‘epineprine’ is not correct and not supported by Goldstein reference — Preceding unsigned comment added by JuliaSimonsen (talk • contribs) 18:11, 22 October 2015 (UTC)

Goldstein ref checked and text corrected